137 related articles for article (PubMed ID: 34261919)
1. Rare anti-VEGFR therapy-induced toxicity and long-term response to immunotherapy in a rare non-clear cell renal cell carcinoma patient.
Catalano F; Rebuzzi SE; Murianni V; Damassi A; Martelli V; Borea R; Rollandi GA; Fornarini G
Anticancer Drugs; 2022 Jan; 33(1):e724-e729. PubMed ID: 34261919
[TBL] [Abstract][Full Text] [Related]
2. Posterior Reversible Encephalopathy Syndrome Associated with Sorafenib and Successful Retreatment.
Laruelle M; Filleul B; Duprez T; Machiels JP
Urol Int; 2018; 100(3):357-360. PubMed ID: 26845702
[TBL] [Abstract][Full Text] [Related]
3. Severe neurological symptoms in a patient with advanced renal cell carcinoma treated with sunitinib.
Duchnowska R; Miciuk B; Bodnar L; Waśniewski L; Szczylik C
J Oncol Pharm Pract; 2013 Jun; 19(2):186-9. PubMed ID: 23037634
[TBL] [Abstract][Full Text] [Related]
4. Posterior reversible encephalopathy syndrome induced by pazopanib for renal cell carcinoma.
Asaithambi G; Peters BR; Hurliman E; Moran BP; Khan AS; Taylor RA
J Clin Pharm Ther; 2013 Apr; 38(2):175-6. PubMed ID: 23210935
[TBL] [Abstract][Full Text] [Related]
5. Reversible posterior leukoencephalopathy syndrome following sunitinib therapy: a case report and review of the literature.
Khan KH; Fenton A; Murtagh E; McAleer JJ; Clayton A
Tumori; 2012; 98(5):139e-142e. PubMed ID: 23235770
[TBL] [Abstract][Full Text] [Related]
6. Reversible posterior leukoencephalopathy syndrome induced by axitinib.
Levy A; Benmoussa L; Ammari S; Albiges L; Escudier B
Clin Genitourin Cancer; 2014 Feb; 12(1):e33-4. PubMed ID: 24135633
[No Abstract] [Full Text] [Related]
7. Optimal management of metastatic renal cell carcinoma: current status.
Escudier B; Albiges L; Sonpavde G
Drugs; 2013 Apr; 73(5):427-38. PubMed ID: 23572408
[TBL] [Abstract][Full Text] [Related]
8. Efficacy and safety of vascular endothelial growth factor receptor tyrosine kinase inhibitors in patients with metastatic renal cell carcinoma and poor risk features.
Lee JL; Park I; Park K; Park S; Ahn Y; Ahn JH; Kim TW; Ahn S; Song C; Hong JH; Kim CS; Ahn H
J Cancer Res Clin Oncol; 2012 Apr; 138(4):687-93. PubMed ID: 22237457
[TBL] [Abstract][Full Text] [Related]
9. Reversible posterior leukoencephalopathy syndrome induced by pazopanib.
Chelis L; Souftas V; Amarantidis K; Xenidis N; Chamalidou E; Dimopoulos P; Michailidis P; Christakidis E; Prassopoulos P; Kakolyris S
BMC Cancer; 2012 Oct; 12():489. PubMed ID: 23088634
[TBL] [Abstract][Full Text] [Related]
10. A phase 2 trial of sunitinib in patients with advanced non-clear cell renal cell carcinoma.
Tannir NM; Plimack E; Ng C; Tamboli P; Bekele NB; Xiao L; Smith L; Lim Z; Pagliaro L; Araujo J; Aparicio A; Matin S; Wood CG; Jonasch E
Eur Urol; 2012 Dec; 62(6):1013-9. PubMed ID: 22771265
[TBL] [Abstract][Full Text] [Related]
11. Optimizing treatment of renal cell carcinoma with VEGFR-TKIs: a comparison of clinical pharmacology and drug-drug interactions of anti-angiogenic drugs.
Fogli S; Porta C; Del Re M; Crucitta S; Gianfilippo G; Danesi R; Rini BI; Schmidinger M
Cancer Treat Rev; 2020 Mar; 84():101966. PubMed ID: 32044644
[TBL] [Abstract][Full Text] [Related]
12. Treatments, Outcomes, and Validity of Prognostic Scores in Patients With Sarcomatoid Renal Cell Carcinoma: A 20-Year Single-Institution Experience.
Korenbaum C; Pierard L; Thiéry A; Story F; Lindner V; Lang H; Kurtz JE; Barthélémy P
Clin Genitourin Cancer; 2018 Jun; 16(3):e577-e586. PubMed ID: 29395949
[TBL] [Abstract][Full Text] [Related]
13. Sunitinib malate for the treatment of renal cell carcinoma.
Wood L
Expert Opin Pharmacother; 2012 Jun; 13(9):1323-36. PubMed ID: 22607009
[TBL] [Abstract][Full Text] [Related]
14. Metastatic clear cell renal carcinoma - an unusual response to Temsirolimus in second line therapy.
Stanculeanu DL; Lazescu A; Zob DD; Bunghez R; Anghel R; Poteca TD
J Med Life; 2016; 9(2):193-8. PubMed ID: 27453754
[TBL] [Abstract][Full Text] [Related]
15. Addressing the best treatment for non-clear cell renal cell carcinoma: A meta-analysis of randomised clinical trials comparing VEGFR-TKis versus mTORi-targeted therapies.
Ciccarese C; Iacovelli R; Brunelli M; Massari F; Bimbatti D; Fantinel E; De Marco V; Porcaro AB; Martignoni G; Artibani W; Tortora G
Eur J Cancer; 2017 Sep; 83():237-246. PubMed ID: 28756136
[TBL] [Abstract][Full Text] [Related]
16. Optimal treatment of poor-risk renal cell carcinoma patients with mTOR inhibitors and anti-VEGFR agents.
Coinu A; Petrelli F; Barni S
Expert Rev Anticancer Ther; 2016; 16(1):33-43. PubMed ID: 26535485
[TBL] [Abstract][Full Text] [Related]
17. Sarcomatoid dedifferentiation in metastatic clear cell renal cell carcinoma and outcome on treatment with anti-vascular endothelial growth factor receptor tyrosine kinase inhibitors: a retrospective analysis.
Beuselinck B; Lerut E; Wolter P; Dumez H; Berkers J; Van Poppel H; Joniau S; Oyen R; De Wever L; Strijbos M; Paridaens R; Schöffski P
Clin Genitourin Cancer; 2014 Oct; 12(5):e205-14. PubMed ID: 24861951
[TBL] [Abstract][Full Text] [Related]
18. Outcomes of patients with metastatic clear-cell renal cell carcinoma treated with second-line VEGFR-TKI after first-line immune checkpoint inhibitors.
Shah AY; Kotecha RR; Lemke EA; Chandramohan A; Chaim JL; Msaouel P; Xiao L; Gao J; Campbell MT; Zurita AJ; Wang J; Corn PG; Jonasch E; Motzer RJ; Sharma P; Voss MH; Tannir NM
Eur J Cancer; 2019 Jun; 114():67-75. PubMed ID: 31075726
[TBL] [Abstract][Full Text] [Related]
19. A phase Ib study of combined VEGFR and mTOR inhibition with vatalanib and everolimus in patients with advanced renal cell carcinoma.
Bitting RL; Healy P; Creel PA; Turnbull J; Morris K; Wood SY; Hurwitz HI; Starr MD; Nixon AB; Armstrong AJ; George DJ
Clin Genitourin Cancer; 2014 Aug; 12(4):241-50. PubMed ID: 24685058
[TBL] [Abstract][Full Text] [Related]
20. VEGFR TKI 'resistance' or transient clinical insensitivity to VEGFR TKI in metastatic renal cell carcinoma.
Ravaud A; Digue L; Trufflandier N; Smith D
Ann Oncol; 2010 Feb; 21(2):431-432. PubMed ID: 19945958
[No Abstract] [Full Text] [Related]
[Next] [New Search]
